FDA Breakthrough Designation · 2026

Innovating Today
For a Healthier Tomorrow

Pioneering breakthroughs in biotechnology to transform lives and shape the future. From drug discovery to bio-manufacturing, we engineer the next generation of medicine.

Explore Solutions → Our Research

// Active Programs

12 in trials

// FDA Designation

Breakthrough

150+

Research Projects

45+

Global Partners

25+

Countries Impacted

10+

Years of Excellence

— Our Core Areas

Four pillars of bioinnovation

From molecule to market, BioNexis covers the entire therapeutic pipeline with deep R&D capability and regulatory expertise.

Drug Discovery

AI-driven target identification accelerating compound validation cycles by 3×.

Genomics

Whole-genome sequencing pipelines for precision diagnostics and personalized treatment design.

Biomanufacturing

GMP-compliant cell & gene therapy production at clinical and commercial scale.

Therapeutics

From oncology to autoimmune — 12 active programs across IND-enabling and late-stage trials.

Active Research Pipeline

Program

Area

Phase

Progress

Status

NX-204 (Solid Tumors)

Oncology

Phase II

▲ Enrolling

NX-118 (mRNA Vaccine)

Infectious Disease

Phase III

▲ On Track

BNX-9 (CRISPR Edit)

Rare Genetic

Phase I

▲ Dosing

NX-Cell-3 (CAR-T)

Hematology

Approved

● Marketed

ATCG · GCAT · TGCA · CGTA · ATCG · GCAT

— Our Approach

Science with a sense
of urgency.

Computational-first discovery

ML models compress 18 months of lab work into 6 weeks of in silico screening.

Translational rigor

Every hit is validated in disease-relevant models before moving to IND-enabling studies.

Patient-centric trials

Decentralized study design and real-world evidence partnerships shrink enrollment timelines.

— Trusted Globally

Partners moving science forward

◉ MERIDIAN PHARMA

◢ AXION LABS

⬡ HELIXBIO

◈ GENOMETRY

⊛ NORTHWAVE TX

⌬ CYNOSURE

Partner with research

Move the next breakthrough into motion.

Share the collaboration type, indication, or investor inquiry and the BioNexis team can route it to the right scientific lead.

1Partner and investor routing 2Pipeline-ready inquiry details 3No clutter around the science story

Innovating TodayFor a Healthier Tomorrow